Orforglipron
Foundayo / oral GLP-1 pill · GLP-1 receptor agonist (oral, FDA-approved)
What it is
Lilly's oral small-molecule GLP-1 agonist — FDA-approved in April 2026 (brand name Foundayo) for chronic weight management, the first GLP-1 pill without food or water timing restrictions.
What human evidence shows
A large Phase 3 program (ATTAIN) showing average weight loss up to roughly 12% at the highest studied dose over 72 weeks, plus A1c reduction — injectable-class results in pill form, now reflected in an approved label.
Risks
GLP-1-class GI effects (nausea, vomiting, constipation), and the label carries the class boxed warning for thyroid C-cell tumors — contraindicated with personal/family history of medullary thyroid carcinoma or MEN2. Now that an approved product exists, anything sold outside pharmacy channels is by definition not the approved drug and has no verifiable identity.
Stacking interactions
Documented interactions with other things people research. A compound not listed here does not mean the combination is safe — only that no specific interaction is on file.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Legal status
US: FDA-approved prescription drug (April 2026). Non-pharmacy "research" versions are unapproved products with no provenance.
Evidence base
substantial literature
Large human evidence base: several phase 3 or 4 trial reports, plus multiple meta-analyses or systematic reviews.
- phase 3/4
- 8
- randomised
- 17
- reviews
- 23
- human trials
- 19
Counts are of published papers, not distinct trials, and measure how much research exists — not whether this works or is safe for you.
Research (12)
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity TreatmentN Engl J Med · 2025
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 DiabetesN Engl J Med · 2025
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ObesityN Engl J Med · 2023
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participantsDiabetes Obes Metab · 2023
- Orforglipron in type 2 diabetes mellitus and obesity: an overviewExpert Rev Clin Pharmacol · 2025
- The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipronSci Transl Med · 2024
- Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysisObes Sci Pract · 2024
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetesDiabetes Obes Metab · 2023
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 studyLancet · 2023
- Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical TrialJAMA · 2026
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trialLancet · 2026
- Orforglipron2012
Turn Orforglipron into a plan that's yours
The info above is free. Membership makes it personal, the Coach answers questions about your exact stack, the Stack tracks it for you, and the Verified Sources shows you how to vet what you buy.
- ✓ AI Coach, ask anything about your stack. It does the dosing math, flags interactions, and tells you what to do next.
- ✓ Personal Stack, save your protocol, track it across devices, log doses, get a heads-up before a vial runs out.
- ✓ Verified Sources, the vetted reference for checking quality and sourcing, members only.
Cancel anytime · or save with $59.99/yr · Coach + Stack included